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The purpose of this paper was to examine and compare available data on incidence, mortality and survival for countries in the Asia-
Pacific region. Incidence data were obtained from GLOBOCAN 2008, other online data sources and individual cancer registries. 
Country-specific mortality statistics by individual year were sourced from the World Health Organization Statistical Information System 
Mortality Database. All incidence and mortality rates were directly age-standardised to the Segi World Standard population and 
joinpoint models were used to assess trends. Data on survival were obtained from country-specific published reports where available. 
Approximately 14% (122,000) of all prostate cancers diagnosed worldwide in 2008 were within the Asia-Pacific region (10 per 100,000 
population), with three out of every four of these prostate cancer cases diagnosed in either Japan (32%), China (28%) or Australia (15%). 
There were also about 42,000 deaths due to prostate cancer in the Asia-Pacific region (3 per 100,000). For the nine countries with 
incidence trend data available, eight showed recent significant increases in prostate cancer incidence. In contrast, recent decreases 
in prostate cancer mortality have been reported for Australia, Japan and New Zealand, but mortality has increased in several other 
countries. The lack of population-based data across most of the countries in this region limits the ability of researchers to understand 
and report on the patterns and distribution of this important cancer. Governments and health planners typically require quantitative 
evidence as a motivation for change. Unless there is a widespread commitment to improve the collection and reporting of data 
on prostate cancer it is likely that the burden of prostate cancer will continue to increase. Enhancing knowledge transfer between 
countries where there are differentials in capacity, policy and experience may provide the necessary impetus and opportunity to 
overcome at least some of the existing barriers.
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INTRODUCTION
Previous international reviews of prostate cancer epidemiol-
ogy have reported high incidence in Western countries, with 
lower but typically increasing incidence in less developed 
countries [1-3]. These varying patterns have been partly at-
tributed to the availability of screening using prostate-specific 
antigen (PSA) to detect asymptomatic tumours, and are also 
linked to a range of other issues such as diet, genetic, lifestyle 
and environmental factors [1,2]. There is much uncertainty 
about the diagnosis and treatment of prostate cancer, with 
disputed interpretations of the benefits of PSA [4,5]. Further-
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der these criteria, Brunei, Malaysia and Fiji were excluded. 
Mortality data for China could not be included as there was 
no category for prostate cancer. 
 Data on survival were obtained from country-specific pub-
lished reports where available. When presenting this informa-
tion we acknowledge the limitations associated with compar-
ing survival statistics across varying time periods, data quality, 
methodologies and clinical characteristics of the patients [17]. 
For this reason we have focussed more on the broad variation 
in survival across the Asian-Pacific countries rather than dif-
ferences in the individual estimates [18]. These statistics were 
supplemented with the mortality:incidence rate ratio (MR:IR) 
to provide approximate estimates of survival for each country 
and to validate the general patterns. Low MR:IR (closer to 
zero) values indicate high survival, while high MR:IR (closer 
to one) values correspond to poor survival.
STATISTICAL METHODS
All incidence and mortality rates were directly age-stan-
dardised to the Segi World Standard population [19]. Rates 
are presented for males of all ages, as well as men aged 50 to 
79 years, where possible, for consistency with previous stud-
ies [20,21]. Trends in prostate cancer incidence and mortal-
ity were assessed using a statistical method called Joinpoint 
analysis [22], which evaluates changing linear trends over 
successive segments of time. This methodology has been used 
in several previous studies that assessed changes in popula-
tion-based trends in prostate cancer incidence or mortality 
[1,3,21,23-25]. A joinpoint can be considered as the point at 
which the linear trend changes significantly in terms of either 
direction or magnitude. To reduce the chance of reporting 
trends that were due to random fluctuations, we set a mini-
mum of six years between a joinpoint and either end of the 
data series, with at least four years of data between joinpoints 
and a maximum of three joinpoints allowed. 
PROSTATE CANCER INCIDENCE
Worldwide, nearly 900,000 men (33 per 100,000 population) 
were estimated to have been diagnosed with prostate cancer 
during 2008 (Table 1). About 14% (122,000) were diagnosed 
within the Asia-Pacific region (10 per 100,000), with three 
out of every four of these prostate cancer cases diagnosed in 
either Japan (32%), China (28%) or Australia (15%). Incidence 
rates varied by almost 50-fold across the region, ranging from 
estimates of between 2 to 3 per 100,000 in North Korea and 
Mongolia up to 100 per 100,000 in New Zealand and 105 per 
more, unlike most other types of cancer, there is no definitive 
recommendation about the optimum management of this 
disease once it is diagnosed [6].
 The purpose of this study was to examine and compare 
data on incidence, mortality and survival for countries in the 
Asia-Pacific region, based on the subregions of Eastern Asia, 
South-Eastern Asia and Oceania as defined by the World 
Health Organization [7]. This area comprises about 32% of 
the world’s male population [8] and includes many nations 
whose populations are increasing rapidly. With its very het-
erogeneous mix of cultures, populations and economies, 
from powerhouses such as Japan, China and Singapore to 
poorer economies typified by those of Laos and Cambodia, 
the Asia-Pacific region provides an ideal opportunity to ex-
plore these variations together with changing patterns, trends 
and influences on prostate cancer epidemiology across the 
different environments. 
DATA SOURCES
GLOBOCAN is a database constructed by the World Health 
Organization (WHO) which contains country-specific esti-
mates of cancer incidence in 2008 for different types of cancer. 
Data quality within GLOBOCAN varies greatly, from accurate 
national information obtained from population-based cancer 
registries to estimates obtained by applying age-specific rates 
from neighbouring countries. We extracted incidence and 
mortality estimates for the countries listed in Table 1, in addi-
tion to totals for the WHO subregions of Eastern Asia, South-
Eastern Asia and Oceania.
 Annual incidence data used in trend calculations were ob-
tained from either online sources (Country/Cancer Registry 
statistics or reports [9-12], Cancer Incidence in Five Continents 
plus [13]), or through contacting individual cancer registries 
and data custodians (Ministry of Health, New Zealand [14]; 
Central Cancer Registry, South Korea [15]). Data were ob-
tained by year of diagnosis as either age-standardised inci-
dence rates, or age-specific incidence counts and populations.
 Country-specific mortality statistics by individual year are 
reported by the WHO in the Statistical Information System 
Mortality Database [16]. Since this database contains only 
actual data provided by countries, rather than estimated data, 
there was a smaller list of countries for which mortality trend 
data was available compared to GLOBOCAN. Furthermore, 
to enable meaningful analysis, Asia-Pacific countries were 
only included in our analysis if they had a minimum of 10 
years data available and at least 100 prostate cancer deaths 
each year (averaged over the most recent 5 year period). Un-
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100,000 in Australia.
 Prostate cancer incidence rates increased with age. In Aus-
tralia and New Zealand, incidence rates rose sharply after 
50 years of age, while in some Asian countries (Japan, Hong 
Kong, and South Korea) the increase was more pronounced 
after 60 years of age (Fig. 1). 
 Prostate cancer was the sixth most frequently diagnosed 
cancer among males during 2008 in the Asia-Pacific region, 
behind cancers of the lung, stomach, liver, colorectum and 
oesophagus [7]. This pattern was mainly driven by Eastern 
Asia, and in particular China, which represents about 62% of 
the region’s male population [8]. However, prostate cancer 
was the most common male cancer in many parts of Oceania, 
including Australia, Fiji, New Caledonia and New Zealand, 
while it ranked second in Brunei, Micronesia, Polynesia and 
Fig. 1. Age-specific incidence rates for prostate cancer, selected 
countries, 2003–2007. Data from: Australia, Australian Institute 
of Health and Welfare [9]; Hong Kong, Hong Kong Cancer Reg-
istry [10]; Japan, Center for Cancer Control and Information Ser-
vices [11]; New Zealand,  Ministry of Health [14]; South  Korea, 
Korea Central Cancer Registry [15].
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the Solomon Islands [7].
 Incidence trends for several countries are shown in Fig. 2 
and Table 2. The most recent trend for each of these countries 
was a significant increase, apart from New Zealand where in-
cidence rates have remained stable since 1995. Of the current 
trends, the largest rise was in South Korea, where incidence 
increased by 13% per year for males of all ages during 1999 to 
2009, closely followed by Shanghai, with an annual increase 
of 12% between 1988 to 2002: Australia, Hong Kong, Japan 
and Singapore (Chinese population only) all recorded recent 
annual increases of around 6%. Smaller, but still significant, 
increases in prostate cancer incidence rates were found for 
males of all ages in the Philippines and Thailand (3% per year 
increase between 1983–2002 and 1983–2009, respectively). 
Similar patterns to the overall trends were observed for those 
countries where annual incidence rates were available for 
men in the 50–79 age group (Table 2). 
PROSTATE CANCER MORTALITY
More than a quarter of a million men (7 per 100,000) were 
estimated to have died from prostate cancer globally during 
2008, including approximately 42,000 deaths (16%) in the 
Asia-Pacific region at a rate of 3 per 100,000 (Table 1). China 
accounted for 34% of prostate cancer deaths within the re-
gion, followed by Japan (24%) and Indonesia (16%). There was 
considerable variation in the age-standardised mortality rate 
for prostate cancer, with mortality in the Oceania subregion 6 
times greater than in Eastern Asia, and 3 times greater than in 
South-Eastern Asia. New Caledonia had the highest country-
specific mortality rate in the Asia-Pacific region of 45 deaths 
per 100,000, however absolute numbers were relatively low.
 Prostate cancer accounted for about 2% of all cancer-relat-
ed deaths in the Asia-Pacific region, ranking eighth compared 
to deaths due to other types of cancer [7]. However, it was the 
most common cause of cancer-related deaths in New Caledo-
nia (26%) and the second most common in Australia (15%), 
New Zealand (14%), Fiji (12%), and Polynesia (10%) [7].    
 There were recent, significant decreases in prostate cancer 
mortality of about 2% per year for males of all ages in Australia 
(1998 to 2006), Japan (2004 to 2010) and New Zealand (1995 
to 2008) (Fig. 3, Table 3). In contrast, mortality rates have in-
creased in other countries, by about 1% per year in Singapore 
(1980–2009) and South Korea (2002–2010), 2% per year in 
Hong Kong (1980–2009), to larger increases of 7% per year 
in the Philippines (1992–2008) and 17% per year in Thailand 
(1994–2006). Similar prostate cancer mortality patterns by 
country were found for men aged 50 to 79 years (Table 3).
PROSTATE CANCER SURVIVAL
There was a large disparity in the survival prospects of men with 
Fig. 3. Prostate cancer mortality rate trends by age for selected Asian-Pacific countries, 1980–2010. Y-axis is shown on a log scale and 
expressed per 100,000 males. Rates were age-standardised to the Segi World Standard Population [19]. Data from World Health Or-
ganization Mortality Database [16]. Population data for the Philippines and Thailand was obtained from the United Nations [8]. 
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prostate cancer throughout the Asia-Pacific region (Table 4). 
Five-year relative survival estimates of 85% and above were 
reported in New Zealand, Australia, Japan, Singapore and 
South Korea. This contrasts with estimated 5-year survival 
rates of between 30% to 40% in parts of China and Thailand.  
 Further evidence supporting these differences in survival 
is gained from the MR:IR ratio, as shown in Fig. 4. The popu-
lation-averaged MR:IR ratio was 0.16 in Oceania, 0.30 in East-
ern Asia and 0.61 in South-Eastern Asia. The MR:IR values in 
specific countries ranged from 0.15 in both Australia and New 
Zealand to over 0.80 in Fiji, Papua New Guinea, East Timor 
and the Solomon Islands. 
 One of the main prognostic factors for prostate cancer is the 
stage (or extent and spread) of the disease at diagnosis, with 
survival outcomes much higher for men diagnosed with lo-
calised disease compared with advanced disease. For example 
in Japan, 5-year relative survival varied from close to 100% for 
localised disease to 87% for regional disease (cancer that had 
grown beyond the original tumour to nearby lymph nodes or 
organs and tissues) and 40% in cases where the cancer had 
spread to distant lymph nodes or organs [11]. This compares 
with corresponding 5-year survival estimates from Singapore 
of 83%, 43% and 23% for localised, regional and distant pros-
tate cancer, respectively [26]. For prostate cancers diagnosed 
Table 4. Estimates of 5-year relative survival for prostate cancer for selected countries in the Asia-Pacific region
Country (registry) Year Method Age Survival categoryb
Australia 2006–2010 Period All High
Japan 2000–2002 Cohort 0–99 High
New Zealand 2008–2009 Period 15–99 High
Singaporea) 2003–2007 Period All High
South Korea 2005–2009 Period All High
China (Hong Kong) 1996–2001 Cohort All Medium
China (Shanghai) 1992–1995 Cohort All Medium
China (Tianjin) 1991–1999 Cohort All Medium
Thailand (Lampang) 1990–2000 Cohort All Medium
China (Qidong) 1992–2000 Cohort All Low
Thailand (Chang Mai) 1993–1997 Cohort All Low
Thailand (Songkhla) 1990–1999 Cohort All Low
Dara from: Australia, Australian Institute of Health and Welfare [49]; China, Hong Kong, Qidong, Shanghai and Tianjin Cancer Registries [50]; Japan, 
Center for Cancer Control and Information Services [11]; New Zealand, Ministry of Health [51]; Singapore, Singapore Cancer Registry [52]; South Ko-
rea, Ministry of Health and Welfare [53]; Thailand, Chaing Mai, Lampang and Songkhla Cancer Registries [50].
a)Survival estimate has been age-standardised to the Segi World Standard Population [19]. b)5-year relative survival estimates were categorised to 
avoid over-interpretation of differences between country estimates, and defined as follows based on rounded estimates: High, ≥85%; medium, 50% 
to 84%; low, <50%. 
Fig. 4. Prostate cancer incidence, mortality and mortality rate:incidence rate ratio (MR:IR) for Asian-Pacific countries, 2008. Rates were 
age-standardised to the Segi World Standard Population and expressed per 100,000 males [19]. MR:IR ratio categories were defined 
based on  quintiles. Incidence categories were approximate quintiles, while mortality matched the incidence categories to enable 
comparison. Data from GLOBOCAN [7].
Incidence Mortality Mortality rate: Incidence rate ratio
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in New South Wales (Australia) between 1999 and 2007, the 
5-year survival ranged from 94% for localised cancers, 86% for 
regional cancers and 17% for distant cancers (personal com-
munication, Dr XQ Yu, Cancer Council NSW). 
VARIATION IN PROSTATE CANCER INCI-
DENCE BETWEEN COUNTRIES
A recent review of the burden of cancer in South East Asian 
nations [27] did not rank prostate cancer within the seven 
most important cancers. In contrast, prostate cancer was the 
most common invasive cancer in Australia and New Zealand 
[7]. The much lower incidence of prostate cancer in many 
countries in the Asia-Pacific region compared with more 
Westernised countries such as Australia and New Zealand 
may reflect differences in the prevalence of risk factors, such 
as genetic predisposition, diet, lifestyle or environment, and/
or it may be as a result of differing utilisation of screening 
through PSA testing. Of note is that the higher rates in Aus-
tralia compared with New Zealand differ from those recently 
reported by Center and colleagues for 2000-2004 [3] reflecting 
the differing recent trends in these two countries.
 It is unclear whether genetics has a major role, with studies 
showing that Asians living in the United States have higher 
incidence rates of prostate cancer than the average rates of 
Asians living in their native countries, however incidence 
rates among Asian Americans are still much lower than non-
Hispanic White Americans [28]. These and other migrant 
studies [29,30] that show consistently higher risks of prostate 
cancer among immigrants and their descendants suggest that 
the Western lifestyle, particularly in relation to diet, plays an 
important role in the aetiology of prostate cancer [25].
 Another contributing cause of international variation is 
likely to be the differing prevalence of PSA testing, where the 
aim is to detect prostate cancer. The increased use of PSA test-
ing can artificially inflate the observed prostate cancer inci-
dence rate because it detects latent, slow growing cancers that 
may not have become symptomatic otherwise. Therefore it is 
highly possible that, with lower rates of PSA testing in many 
Asian countries compared with Australia and New Zealand, 
much of the observed differential in prostate cancer incidence 
rates throughout the Asia-Pacific region may be due to differ-
ences in PSA testing [2]. Ironically, this contrasts completely 
in relation to the impact of the implementation of screening 
for cervical cancer through Pap smear testing, where the in-
tention is to detect precancerous lesions, thus reducing the 
cancer incidence rate. Cervical cancer is the second most 
diagnosed cancer in South East Asia, and the third most com-
mon cause of cancer deaths, which has been linked in part to 
a lack of screening [27].
 Unfortunately there are only limited data on the preva-
lence of PSA testing or screening across these countries. In 
Queensland (Australia) in 2004, 52% of men aged 50 to 75 years 
reported to have ever had a PSA test [31], while the annual rate 
of PSA testing in Australia in 2008/09 was between 21,000 and 
25,000 tests per 100,000 men (21–25%) aged 50 to 79 years [23]. 
New Zealand had similar proportions, with 49% of men aged 
40 to 74 years reporting having ever had a PSA test, and 22% 
within the previous 5 years [32]. In Japan the percentage of 
men over 50 years of age who received PSA screening was esti-
mated to be less than 20% [33]. In South Korea only 15% of men 
aged over 50 in 2004 reported having been screened during the 
previous 2 years [34].
 However, much of the evidence for limited PSA testing is 
anecdotal, and based on the stage at which prostate cancers 
are diagnosed. Since PSA testing aims to detect asymptom-
atic cancers, it follows that countries with high proportions of 
prostate cancers that are localised would be more likely have 
higher rates of PSA testing. There have been calls for increases 
to PSA testing in several Asia Pacific countries because most 
of the prostate cancers detected are well advanced with poor 
prognoses [2,35,36]. Prostate cancer in Malaysia and rural 
China is typically a disease diagnosed at a more advanced 
stage at diagnosis [35,36]. In Malaysia, for example, one in-
stitutional study found over half of prostate cancers were 
already at Stage 4 [36] compared with less than 20% in Japan 
[11]. This was also evidenced in the data we have presented, 
with higher rates of 5-year survival and much lower values 
for MR:IR in Australia, New Zealand, and Japan compared to 
many other countries in the Asia-Pacific region. 
INCREASING PROSTATE CANCER  
INCIDENCE
In addition to the wide variations in incidence rates across 
countries, the epidemiology of prostate cancer in the Asia-
Pacific region is characterised by a generally increasing in-
cidence burden, something also seen in many northern and 
western European countries [3]. There are several potential 
explanations for this trend in the Asia-Pacific region.
 While the exact causes of prostate cancer are unclear, as al-
ready mentioned there is suggestive evidence for an impact of 
Western lifestyle. Many countries in the Asia-Pacific have ex-
perienced a shift from traditional high fibre and carbohydrate 
diets based on vegetable foods to a westernised diet that cen-
tres around red or processed meat with high total and satu-
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rated fat content [25,37,38]. This shift has been typically moti-
vated by strong economic growth and the resulting increases 
in average family incomes. Unfortunately this changing diet 
with its increased energy intake has been accompanied by 
lower levels of physical activity, leading to an increased preva-
lence of persons who are overweight or obese [25]. The World 
Cancer Research Fund and American Institute for Cancer 
Research estimated that 16% of prostate cancers could be pre-
vented worldwide if the exposures of poor nutrition and diet, 
physical inactivity and obesity were eliminated, while leaving 
other risk factors unchanged [39].
 As our results demonstrate, the majority of prostate cancer 
cases are diagnosed between 50–79 years of age. The age dis-
tribution of a population therefore has a major influence on 
the absolute numbers of men diagnosed with prostate cancer. 
Given that life expectancy is expected to increase markedly in 
many parts of Asia over coming years [27,40,41], the burden 
of prostate cancer in this region is likely to be a high priority 
in the future [42].
 PSA testing is also likely to have an important influence on 
the increasing incidence of prostate cancer. As prostate can-
cer becomes more common it leads to greater public aware-
ness, which in turn prompts asymptomatic men to request 
PSA testing while also stimulating general practitioners to 
utilise it as a screening tool [41]. Indeed, the increasing inci-
dence of prostate cancer in Singapore has been suggested to 
be due to more widespread, although still ad hoc, use of PSA 
testing [40].
 At the same time, it is increasingly recognised that testing 
of asymptomatic men with the PSA test is resulting in over di-
agnosis of the disease due to the detection of cancers that are 
not clinically significant [43], prompting one commentator 
to note that “limiting the extent of PSA testing would be one 
of the means to reduce the prevalence of prostate cancer” 
[44]. While this may hold some truth, mortality rates are also 
increasing in several countries in the Asia-Pacific along with 
increasing incidence rates, which suggests that at least some 
of the increasing incidence is related to tumours that have the 
capacity to progress.
VARIATION IN PROSTATE CANCER  
MORTALITY TRENDS BETWEEN  
COUNTRIES
Stark differences in prostate cancer mortality trends in the 
Asia-Pacific region were found between more developed 
countries (Australia, New Zealand, and Japan), where mor-
tality has begun to significantly decrease, as opposed to less 
developed countries such as the Philippines and Thailand 
where large increases in mortality over recent years have been 
observed.  
 The reasons for this variation are likely to be multifaceted. 
Refinements to treatment and management of early stage 
prostate cancers [45] and easier access to these treatments 
in more developed countries would be one of the main driv-
ers. PSA testing may also be involved in terms of increasing 
the proportion of cases where the disease is treatable [46], al-
though opinion remains divided on the ability of screening to 
reduce mortality [4,5]. The fact that incidence rates are gener-
ally continuing to increase in those countries where mortality 
rates are decreasing suggests against a change in the preva-
lence of risk factors for prostate cancer being a contributing 
element [47].
CONCLUSION
Prostate cancer in the Asia-Pacific region is characterised 
by wide variations in incidence and mortality, combined 
with evidence of an increasing burden of incidence in many 
areas. The lack of population-based data across most of the 
countries in this region limits the ability of researchers to un-
derstand and report on the patterns and distribution of this 
important cancer. Potential solutions will require a long-term 
commitment, and involve the implementation of registration 
and reporting mechanisms that currently may not be feasible. 
However governments and health planners typically require 
quantitative evidence as a motivation for change. Unless there 
is a widespread commitment to improve the collection and 
reporting of data on prostate cancer, including the provision 
of international assistance, it is likely that the burden of pros-
tate cancer will continue to increase. Enhancing knowledge 
transfer from country to country where there are differentials 
in capacity, policy and experience may provide the necessary 
impetus and opportunity to overcome at least some of the ex-
isting barriers. 
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